Clinical trials: Arsenic Trioxide
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Oral-ATO for TP53-mutated Myeloid Malignancies
This is an open-label, phase 2 study of oral arsenic trioxide (Arsenol ®) in combination with ascorbic acid and investigator choice of low-intensity therapy in patients with previously untreated or relapse/refractory TP53-mutated…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, TP53 Gene Mutation
- Trial name
- NCT06778187
- Testing
- Oral arsenic trioxide
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Arsenic Trioxide, Childhood ALL
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%.
- Trial name
- SCCCG-R-ALL (NCT05682131)
- Testing
- Realgar Indigo naturalis formula, Conventional chemotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Arsenic Trioxide, p53 Mutations
Arsenic Trioxide for Structural p53 Mutations
TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with…
- Conditions
- Arsenic Trioxide, p53 Mutations, Refractory Cancer, Intractable Cancer
- Trial name
- NCT04695223
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital